-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, according to the Insight database, BeiGene registered and started the clinical trial of the TYK2 inhibitor BGB-23339 for the first time in China
From: Insight Database applet
TYK2, a member of the JAK kinase family, functions as a key regulator of cytokine signaling pathways in a variety of immune-mediated diseases, including psoriasis and inflammatory bowel disease
BGB-23339 is a potent and highly selective investigational tyrosine kinase 2 (TYK2) allosteric inhibitor targeting the regulatory pseudokinase (JH2) domain of TYK2
A Phase 1 clinical trial of BGB-23339 is expected to enroll as early as September 2021, with plans to enroll 115 healthy subjects in Australia and China
Overview of the Global Indication Development of the BGB-23339 Project
From: Insight Database Global New Drug Module (http://db.
At present, in addition to BeiGene, Bristol-Myers Squibb and Pfizer have also launched clinical trials of TYK2 selective inhibitors in China
Among domestic companies, Nuocheng Jianhua has developed two TYK2 inhibitors, ICP-332 and ICP-488, both of which have been approved for clinical use; Hangzhou Gaoguang Pharmaceutical’s TLL-018 has also been launched for rheumatoid arthritis and ulcerative colitis Phase II clinical trials
Domestic enterprise TYK2 inhibitor project
From: Insight database applet (http://db.
Note: The original text has been deleted
